KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $2.8 billion.

  • Biogen's Other Accumulated Expenses fell 18.16% to $2.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.8 billion, marking a year-over-year decrease of 18.16%. This contributed to the annual value of $2.8 billion for FY2025, which is 18.16% down from last year.
  • Biogen's Other Accumulated Expenses amounted to $2.8 billion in Q4 2025, which was down 18.16% from $2.8 billion recorded in Q3 2025.
  • Biogen's Other Accumulated Expenses' 5-year high stood at $3.8 billion during Q3 2023, with a 5-year trough of $2.2 billion in Q1 2022.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $2.6 billion (2021), whereas its average is $2.7 billion.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 2960.76% in 2022, then plummeted by 2822.27% in 2024.
  • Quarter analysis of 5 years shows Biogen's Other Accumulated Expenses stood at $2.5 billion in 2021, then decreased by 0.54% to $2.5 billion in 2022, then increased by 4.05% to $2.6 billion in 2023, then rose by 7.02% to $2.8 billion in 2024, then decreased by 0.18% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q4 2025, $2.8 billion for Q3 2025, and $2.7 billion during Q2 2025.